Collplant Biotechnologies LTD (CLGN) — SEC Filings

Overview

Collplant Biotechnologies LTD (CLGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 22, 2026: CollPlant Biotechnologies Ltd. filed an EFFECT form on April 22, 2026, indicating the effectiveness of a registration statement. The filing relates to Act 33 and has the file number 333-294738. The company's business address is 4 Oppenheimer St., 11th Floor, Rehovot, L3 74140.

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 7 bullish, 1 bearish, 23 neutral, 2 mixed. The dominant filing sentiment for Collplant Biotechnologies LTD is neutral.

Filing Type Overview

Collplant Biotechnologies LTD (CLGN) has filed 1 EFFECT, 3 20-F, 27 6-K, 2 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (33)

• CollPlant Biotechnologies SEC Filing Effectiveness — EFFECT · Apr 22, 2026 Risk: medium
  CollPlant Biotechnologies Ltd. filed an EFFECT form on April 22, 2026, indicating the effectiveness of a registration statement. The filing relates to Act 33 an
• CollPlant Faces Going Concern Doubt Amidst R&D-Heavy Strategy — 20-F · Mar 26, 2026 Risk: high
  CollPlant Biotechnologies Ltd. (CLGN) reported significant losses for the fiscal year ended December 31, 2025, and anticipates continued losses, raising substan
• CollPlant Biotechnologies Files December 2025 6-K Report — 6-K · Dec 31, 2025 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K for the month of December 2025. This report is for a foreign private issuer and is incorporated by reference int
• CollPlant Biotechnologies Files November 2025 6-K Report — 6-K · Nov 26, 2025 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on November 26, 2025, reporting on their activities for the month of November 2025. The filing includes a press
• CollPlant Expands rhCollagen Distribution Network — 6-K · Oct 27, 2025 Risk: low
  On October 27, 2025, CollPlant Biotechnologies Ltd. announced an expansion of its rhCollagen distribution network. The company issued a press release detailing
• CollPlant's Vergenz Bio-Ink Shows High Success in Diabetic Foot Ulcer Trial — 6-K · Oct 20, 2025 Risk: medium
  On October 20, 2025, CollPlant Biotechnologies Ltd. issued a press release announcing the successful completion of a clinical trial for its Vergenz™ rhCollagen-
• CollPlant Unveils Novel 3D Bioprinted Osteoarthritis Treatment — 6-K · Oct 16, 2025 Risk: medium
  On October 16, 2025, CollPlant Biotechnologies Ltd. announced the successful development of a first-in-kind fully humanized 3D bioprinted regenerative medicine
• CollPlant Biotechnologies Files 6-K Report — 6-K · Sep 30, 2025 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on September 30, 2025, reporting for the month of September 2025. The filing is a report of a foreign private is
• CollPlant Expands Vergenix Distribution — 6-K · Sep 15, 2025 Risk: medium
  On September 15, 2025, CollPlant Biotechnologies Ltd. announced an expansion of the distribution of its Vergenix® product line. This expansion will include new
• CollPlant Seeks Nasdaq Upgrade — 6-K · Sep 12, 2025 Risk: low
  CollPlant Biotechnologies Ltd. submitted a voluntary application on September 12, 2025, to transfer the listing of its ordinary shares from the Nasdaq Capital M
• CollPlant Biotechnologies Files 6-K Report — 6-K · Aug 20, 2025 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on August 20, 2025, reporting for the period ending June 30, 2025. The company, incorporated in Israel, operates
• CollPlant Appoints Collagen Biomaterials Expert as CSO — 6-K · Jul 14, 2025 Risk: low
  CollPlant Biotechnologies Ltd. announced on July 14, 2025, the appointment of Dr. Elka Touitou as Chief Scientific Officer. Dr. Touitou, a recognized expert in
• CollPlant Expands STEMCELL Collaboration — 6-K · Jun 9, 2025 Risk: low
  On June 9, 2025, CollPlant Biotechnologies Ltd. announced an expansion of its collaboration with STEMCELL Technologies Inc. This expanded agreement focuses on t
• CollPlant Biotechnologies Secures European Patent for BioInk — 6-K · Jun 4, 2025 Risk: low
  CollPlant Biotechnologies Ltd. announced on June 4, 2025, that it has been granted a European patent for its "BioInk" technology. This patent covers the use of
• CollPlant Biotechnologies Files June 2025 6-K Report — 6-K · Jun 2, 2025 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on June 2, 2025, reporting on its activities for the month of June 2025. The filing is a report of a foreign pri
• CollPlant Biotechnologies Files May 2025 6-K Report — 6-K · May 30, 2025 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on May 30, 2025, reporting on its activities for the month of May 2025. The filing includes a press release, whi
• CollPlant Biotechnologies Reports Q1 2025 Financials — 6-K · May 28, 2025 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on May 28, 2025, reporting its first quarter 2025 financial results and balance sheet and cash flow information.
• CollPlant Bio's Collink.3D® Shows High Success in Bone Regeneration Study — 6-K · Apr 15, 2025 Risk: medium
  On April 15, 2025, CollPlant Biotechnologies Ltd. announced the successful completion of a clinical study for its Collink.3D® bio-ink, demonstrating significant
• CollPlant Biotechnologies Files 2024 Annual Report — 20-F · Mar 26, 2025 Risk: medium
  CollPlant Biotechnologies Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in L3 and headquarter
• CollPlant Biotechnologies Files Form 6-K for February 2025 — 6-K · Feb 24, 2025 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on February 24, 2025, reporting for the month of February 2025. The filing incorporates by reference the first p
• CollPlant Gets New Patent for Dermal Filler — 6-K · Feb 12, 2025 Risk: low
  CollPlant Biotechnologies Ltd. announced on February 12, 2025, that it has been granted an additional patent for its photocurable dermal filler program. This pa
• CollPlant Biotechnologies Files 6-K with Q3 2024 Financials — 6-K · Nov 27, 2024 Risk: medium
  CollPlant Biotechnologies Ltd. filed a Form 6-K on November 27, 2024, reporting financial results for the three- and nine-month periods ended September 30, 2024
• CollPlant Biotechnologies Files September 2024 6-K Report — 6-K · Sep 25, 2024 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on September 25, 2024, to report on its activities for the month of September 2024. The filing is a report of a
• CollPlant Biotechnologies Files August 2024 6-K Report — 6-K · Aug 20, 2024 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on August 20, 2024, reporting on its activities for the month of August 2024. The filing is a report of a foreig
• CollPlant to Acquire Nano-X Imaging for $126M — 6-K · Aug 19, 2024 Risk: medium
  CollPlant Biotechnologies Ltd. announced on August 19, 2024, that it has entered into a binding agreement to acquire Nano-X Imaging Ltd. for approximately $126
• CollPlant Biotechnologies Unveils Inaugura 3D Bioprinting Platform — 6-K · Jul 29, 2024 Risk: medium
  On July 29, 2024, CollPlant Biotechnologies Ltd. issued a press release announcing the unveiling of its "Inaugura" 3D bioprinting platform. This platform is des
• CollPlant to Acquire Nano-X Imaging for $126M — 6-K · Jun 6, 2024 Risk: medium
  CollPlant Biotechnologies Ltd. announced on June 6, 2024, that it has entered into a binding agreement to acquire Nano-X Imaging Ltd. for approximately $126 mil
• CollPlant Biotechnologies Reports Q1 2024 Financial Results — 6-K · May 29, 2024 Risk: low
  CollPlant Biotechnologies Ltd. filed a Form 6-K on May 29, 2024, reporting its first quarter financial results. The filing details the company's financial perfo
• CollPlant Biotechnologies Ltd. Files 20-F Annual Report for Fiscal Year Ended Dec 31, 2023 — 20-F · Apr 4, 2024 Risk: low
  CollPlant Biotechnologies Ltd (CLGN) filed a Foreign Annual Report (20-F) with the SEC on April 4, 2024. CollPlant Biotechnologies Ltd. filed its annual report
• CollPlant 6-K Reports 2023 Shareholder Letter — 6-K · Feb 15, 2024 Risk: medium
  CollPlant Biotechnologies Ltd. filed a Form 6-K on February 15, 2024, to report a press release that was issued on February 15, 2023. The press release was titl
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Loewenbaum Group Amends CollPlant Biotechnologies Stake — SC 13G/A · Jan 25, 2024
  Lillian S. Loewenbaum and related entities, including various trusts and partnerships, filed an amended Schedule 13G/A on January 25, 2024, for their holdings i
• CollPlant Begins Preclinical Trials for Regenerative Breast Implants — 6-K · Jan 2, 2024
  CollPlant Biotechnologies Ltd. announced on January 2, 2024, that it has started preclinical trials for its commercial-size, regenerative breast implants. This

Risk Profile

Risk Assessment: Of CLGN's 30 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Yehiel Tal
• Dr. Elka Touitou

Industry Context

The medical aesthetics and regenerative medicine industries are characterized by rapid technological advancements and significant investment. Companies are increasingly focusing on biomaterials and 3D printing to develop innovative solutions for tissue repair and aesthetic enhancement. CollPlant operates within this dynamic landscape, facing competition from established players and emerging biotech firms.

Top Tags

biotechnology (14) · foreign-private-issuer (9) · sec-filing (6) · reporting (5) · 6-K (5) · regenerative-medicine (5) · regulatory-filing (5) · medical-devices (3) · financial-results (3) · press-release (2)

Key Numbers

• File Number: 333-294738 — Associated with the registration statement
• CIK: 0001631487 — CollPlant Biotechnologies Ltd identifier
• Ordinary Shares Outstanding: 12,803,006 — As of December 31, 2025, indicating the current equity base.
• Par Value per Share: NIS 1.50 — The nominal value of each ordinary share.
• Fiscal Year End: 2025 — The period covered by this annual report, showing the company's financial status for that year.
• Allergan Agreement Year: 2021 — The year CollPlant entered into a significant development and commercialization agreement with Allergan, an AbbVie company.
• Complete Wound Closure: 88% — Achieved in patients treated with Vergenz™ for diabetic foot ulcers within 12 weeks.
• Treatment Duration: 12 weeks — The timeframe within which complete wound closure was observed in the successful trial.
• SEC File Number: 001-38370 — Identifies the company's registration with the SEC.
• Patients: 20 — Number of participants in the clinical study
• Success Rate: 90% — Achieved bone fusion rate in the study
• Time to Fusion: 6 months — Duration for bone fusion observed in the study
• Acquisition Value: $126M — Total consideration for Nano-X Imaging Ltd.
• Filing Date: 20240404 — Filed as of date
• Outstanding Ordinary Shares: 11,452,672 — As of December 31, 2023

Related Companies

ABBV · PLNT · NNOX

Frequently Asked Questions